Trials / Completed
CompletedNCT07071701
A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population Aged 2 Years and Above
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 19,267 (actual)
- Sponsor
- Sinovac Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Accepted
Summary
An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years and above. All participants received 1 dose of PPV23 and self-selected whether to receive 1 dose of influenza vaccine at the same time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 23-valent pneumococcal polysaccharide vaccine | 23-valent pneumococcal polysaccharide vaccine |
| BIOLOGICAL | Influenza vaccine | Influenza vaccine |
Timeline
- Start date
- 2022-07-02
- Primary completion
- 2024-04-05
- Completion
- 2024-04-05
- First posted
- 2025-07-17
- Last updated
- 2025-07-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07071701. Inclusion in this directory is not an endorsement.